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Pertussis is a contagious respiratory disease that can occur in all age groups. Signs
and symptoms of pertussis, however, are worse in infants and young children; likewise,
the rates of severe cases, hospitalizations, and deaths are higher in this group as well.
Vaccination against pertussis is the most effective way to combat this illness. In the last
15 years, there have been a number of changes in the recommendations regarding
vaccination against pertussis. In order for these recommendations to be followed,
healthcare professionals must be aware of the guidelines as well as be knowledgeable
about the condition they are trying to prevent.
This study evaluated the knowledge and practice of obstetrics healthcare
professionals in Bartlesville, Oklahoma, regarding maternal pertussis vaccination
strategies and timing. It assessed their perceived knowledge and practice before an
educational in-service regarding pertussis prevention strategies specifically related to
pertussis vaccination and pregnancy. Immediately following the educational in-service,
healthcare professionals were asked to report whether they had an increase in knowledge
regarding pertussis and vaccination strategies and whether they plan to change their
practice in the future as a result of information received. The participants of this study
reported having an increase in knowledge regarding pertussis and vaccination strategies,
as well as an intention to use the information in the future for patient education.
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Chapter I

Introduction

Throughout history a major cause of infant morbidity and mortality has been
pertussis, also known as “whooping cough.” After the introduction of the pertussis
vaccine in the 1940’s, the number of cases declined significantly. Unfortunately, pertussis
once again threatens young infants despite vaccination efforts and availability (Forsyth et
al., 2015).
Pertussis is a highly contagious acute respiratory illness caused by Bordetella
pertussis, which is transmitted by aerosolized droplets (Cornia & Lipsky, 2017).
Vaccination is the primary method for preventing pertussis. Despite the availability of
vaccination, increased incidence of pertussis continues even in populations with rate of
high vaccine coverage. The primary source of pertussis in infants is direct family
members, with parents contributing in 50-55% of reported cases (Wiley et al., 2013).
Grandparents and adolescent siblings accounted for 8% and 20% transmission rates,
respectively (Terranella et al., 2013).
In adults and adolescents, clinical manifestations of pertussis are often less severe
than in infants and children. If a person has received immunization previously, a
prolonged cough may be the only symptom. Others may include increased sputum
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production, sweating episodes, and sore throat. Complications of pertussis can result in
pneumonia or otitis media (Cornia & Lipsky, 2017).
Description of the Clinical Problem
Bordetella pertussis can lead to serious manifestations in young infants, who are
more susceptible (Walther et al., 2015). Clinical signs include respiratory distress such as
rapid breathing, grunting, nasal flaring, and retractions. Other manifestations can include
pneumonia, inability to feed, cyanosis, apnea with or without coughing, and seizures.
Decreases in fluid or nutrition intake combined with possible vomiting while coughing
can lead to ceasing or declining weight gain, resulting in a failure to thrive diagnosis
(Yeh, 2017).
Pertussis Vaccination
In the early 1900s, a vaccine was developed using killed whole cell pertussis
(wP). Later in the 1970s and 1980s, acellular pertussis (aP) vaccines were developed. The
acellular pertussis vaccines had a lower rate of adverse reactions and were shown to also
be effective against pertussis. This is the vaccine of choice today because of the lower
incidence of side effects, but the whole cell vaccine may offer a higher level of immunity.
The aP component is combined with the combination tetanus and diphtheria (Td)
components to create the DTaP for children up to six years of age and Tdap vaccine for
those over the age of seven (Chiappini, et al., 2013).
Infants are not initially immunized against pertussis until two months of age and
depend upon others to not expose them to the illness. Primary immunization is comprised
of five doses of the DTaP vaccine. In their first year, infants receive doses of the pertussis
vaccine at two months, four months, and six months of age. The fourth dose is
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administered at 18 months of age, and fifth dose around 4-6 years of age. Immunizations
are specifically timed in order to gradually establish stronger immunity to the pertussis
antigen. Between the first and fifth doses, the infant builds antibodies and generally has
partial immunity. Young children remain vulnerable before the initial vaccine, but the
risk of infection is decreased. After the first dose of DTaP, the vaccine effectiveness is
only 55.3%, this increases to approximately 80% after the second dose (Quinn et al.,
2014). With this in mind, it is possible to further protect infants and young children with
incomplete immunity by having high levels of herd immunity in another group.
Herd Immunity
Herd immunity, also known as community immunity or herd protection, may
develop naturally in society as a result of large-scale exposure to and recovery from
disease; it may be stimulated artificially by widespread vaccination programs. Immunity
is actively or passively acquired. Active immunity is the most common contributor to
herd immunity. In active immunity, the individual develops resistance to a disease as a
result of antibody production in relation to the exposure to and recovery from an antigen
or after immunization (Merrill, 2013). Immunity limits or stops the ability of an
individual to acquire and or pass along a specific disease (McCance & Huether, 2014).
The easiest and safest way to increase levels of immunity results from vaccination (Fine
et al., 2011). An individual’s immune system cannot distinguish between a vaccination or
natural infection, so it creates antibodies and an immune reaction in response to both;
however, vaccines usually have fewer side effects and complications associated with
them (Pommerville, 2014).
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Infants and young children can be partially protected from pertussis with high
levels of immunity in adolescents and young adults. With this concept in mind, in 2005
the Advisory Committee on Immunization Practices (ACIP) introduced the concept of
“cocooning,” a form of herd immunity (as cited in Terranella et al., 2013). With herd
immunity, an individual is thought to be protected from a disease if those around him are
vaccinated against that disease. This decreases the likelihood of the individual coming
into contact with an infected person. Family members who have not received a Tdap
booster, including fathers and adolescent siblings, are encouraged to receive a booster
vaccination of Tdap before the birth of an infant if not previously vaccinated. This allows
the ability to shield or “cocoon” the infant with immunity. As a part of the cocooning
strategy, mothers were also instructed to receive the vaccine in the immediate postpartum
period, referred to as postpartum vaccination.
Issue Significance
Despite the initiatives created in 2005, pertussis cases and rates continued
significantly in the infant population. Between 2001 and 2010 there were 27,995 reported
cases of pertussis in infants less than one year of age in the United States. In this group
there were a resulting 189 deaths. The majority of these deaths occurred among those less
than 3 months old (Centers for Disease Control, 2017). In infants less than two months
old, pertussis cases accounted for 57% of hospitalizations and 85% of deaths (Terranella
et al., 2013).
While pertussis can be prevented by immunization, lifelong protection, however,
cannot be achieved by initial immunization or natural disease (Walther et al., 2015).
Immunity coverage for pertussis is restricted to five to eight years, after natural infection,
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or vaccination; for this reason, regular booster doses are needed (Chiappini et al., 2013).
Due to decreasing immunity, adolescents should receive a Tdap booster immunization at
11 to 18 years of age (Cornia & Lipsky, 2017). The ACIP recommends that adolescents,
adults, and those over the age of 65 receive a dose of Tdap, especially if they are in close
contact with infants (Chiappini et al., 2013). Tdap should be the vaccine of choice over
regular tetanus and diphtheria (Td) immunization because it boosts immunity to tetanus
and pertussis. It is recommended that a booster of Tdap be administered every 10 years, if
not indicated sooner.
Due to continued cases of pertussis, the ACIP introduced new guidelines in 2012,
recommending that women should receive a Tdap vaccination during every pregnancy
between 27-36 weeks gestation regardless of previous vaccination status. This dose is
deemed the prenatal or pregnancy vaccination (as cited in Centers for Disease Control,
2018). It allows the mother to create antibodies which will provide direct immunity to the
mother and indirect or passive immunity to the infant. During pregnancy, antibodies from
the mother cross the placental barrier to the infant and can remain present in the infant for
up to 35-55 days after birth (Abu Raya et al., 2015). This transfer of antibodies is able to
offer a small degree of protection to the infant until they are able to start receiving
vaccinations of their own.
Specific Purpose
Although steps continue to be made regarding recommendations and current
vaccination efforts, pertussis rates continue to increase due to decreases in vaccination
uptake and waning immunity of those previously vaccinated against pertussis. Infants are
at an extreme disadvantage since they do not receive their first dose of DTaP until 2
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months of age. To best combat this, mothers must receive the Tdap vaccination with
every pregnancy to transfer a small amount of immunity to the infant. This practice has
been lacking in acceptance among patients as well as implementation among healthcare
providers.
To establish a greater overall immunity to pertussis, it must be determined how to
best implement and educate the public about these strategies. A lack of public knowledge
about waning immunity associated with Tdap vaccination was observed as a barrier to
individuals obtaining a booster vaccination. A study conducted by Suryadevera et al.
(2014) examined reasons for low immunity coverage. Participants took a survey that
inquired about factors such as knowledge about pertussis, receipt of booster vaccination,
and instruction by a health provider to obtain a booster vaccination. Results determined a
significant lack of knowledge concerning the disease as well as a lack of provider
recommendation to receive the vaccination.
This scholarly project will evaluate provider knowledge regarding current
recommendations concerning maternal prenatal pertussis vaccination before and after a
teaching in-service. The in-service will highlight the current ACIP Tdap guidelines and
outline specific instances which require Tdap administration to intrapartum and
postpartum mothers. The use of a postintervention survey will determine the knowledge
gained during the in-service as well as the provider’s intention of using it in practice.
Theoretical Framework
The theoretical framework for this project uses the Health Belief Model. This
model was developed in the 1950’s by Godfrey Hochbaum, Irwin Roenstock, and Steven
Kegels to increase disease prevention. It was created in response to a failing free health
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screening program for tuberculosis. The Health Belief Model has been utilized to
describe and promote safety initiatives such as use of seatbelts, oral contraceptives, safe
sex practices, health screenings, as well as vaccination programs (ReCAPP, 2018).
The Health Belief Model outlines two beliefs about a particular negative health
outcome outlined as an individual’s susceptibility and severity. These outcome beliefs are
balanced against two beliefs about the behavior to prevent the negative outcome
including perceived benefits and barriers of the individual. These four beliefs drive a
person to act or not act to prevent the outcome. To begin, an individual must believe
whether or not they are susceptible to a negative outcome and must also believe whether
or not they perceive the outcome to be severe. Once a person is convinced of the severity
of the illness or outcome and his susceptibility, he will take into consideration the
benefits of the proposed behavior. These benefits may be universally inherent to all
individuals, may be specific for that individual, or may be a combination. A factor that
may stand in the way of a person completing the desired task is perceived barriers. Again,
these may also be universal to all individuals, may be specific for that person, or more
than likely will be a combination. Barriers can include monetary commitment, time
constraint, and perceived pain. Other strong barriers can come from level of education
and cultural or familial beliefs (Resource Center for Adolescent Pregnancy Prevention,
2020).
Finally, in order to act, influencing factors must be strong enough to overcome a
person’s perceived barriers to completing the behavior (Resource Center for Adolescent
Pregnancy Prevention, 2020). Factors influencing behavior are also called cues to action.
These factors include outside influences such as family advice and tradition as well as
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information received from a health care provider. Other cues include national and local
health initiatives, and advertisements.
Once all the available factors have been received by the individual, the perceived
benefits minus the personal barriers result in the likelihood of a person following through
with a desired outcome or behavior. While this model can help explain an individual’s
behavior, it is not meant to be used as a risk assessment, and factors are not considered
indicators for definite action or lack of action.
The basis of this project and overall focus will center around the knowledge of
healthcare professionals regarding maternal Tdap recommendations and their current
practice discussing recommendations with their patients. Education from health care
professionals is an important cue to action that can help patients make better informed
decisions regarding healthcare for themselves or family members. This project also
worked to determine the current influence from healthcare professionals and whether that
influence could be stronger as well as help determine if there is a lack of or error in the
information being provided to patients from healthcare workers.
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Figure 1:
Health Belief Model

Project Questions
1. What is the current knowledge level, attitude, and belief of physicians,
advanced practice providers, and support staff of obstetric clinics at St. John
Medical Group in Bartlesville, Oklahoma, regarding national maternal Tdap
vaccination guidelines?
2. How will the knowledge, attitude, and beliefs of these healthcare professionals
change after receiving education regarding Tdap administration guidelines?
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Definition of Key Terms
The key terms and definitions below will provide a basis for the important
considerations of this project:
•

DTaP- diphtheria, tetanus, and acellular pertussis vaccine, which is given to
children (CDC, 2019a).

•

Tdap- combined tetanus, diphtheria and acellular pertussis vaccine, which is given
to adolescents and adults (CDC, 2019a).

•

Booster- a dose of an immunizing substance given to maintain or renew the effect
of a previous one (Dictionary.com, n.d).

•

Barrier- anything that restrains or obstructs progress (Dictionary.com, n.d).

•

Herd Immunity- the ability of a community to resist epidemic disease (Taber’s,
1997).

•

Prenatal- occurring, existing, performed, or used before birth (Merriam-Webster
Dictionary, n.d.).

•

Intrapartum- occurring or provided during the act of birth (Merriam-Webster
Dictionary, n.d.).

•

Postpartum- occurring in or being the period following childbirth (MerriamWebster Dictionary, n.d.).

•

Healthcare Professional- a person associated with either a specialty or a discipline
and who is qualified and allowed by regulatory bodies to provide a healthcare
service to a patient (FreeDictionary.com, n.d.).
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•

Primary Care Provider- a health care practitioner who sees people who have
common medical problems. This person is usually a doctor but may be a
physician assistant or a nurse practitioner (Medline Plus, 2014).

•

Family Practice Physician- Doctors who have completed a family practice
residency and are board-certified, or board-eligible, for this specialty. The scope
of their practice includes children and adults of all ages and may include
obstetrics and minor surgery (Medline Plus, 2014).

•

Obstetrician/gynecologists (OB/GYN)- Doctors who have completed a residency
and are board-certified, or board-eligible, in this specialty. They often serve as a
primary care provider for women, particularly those of childbearing age (Medline
Plus, 2014).

•

Inpatient- a hospital patient who receives lodging and food as well as treatment
(Merriam-Webster Dictionary, n.d.).

•

Outpatient- a patient who is not hospitalized overnight but who visits a hospital,
clinic, or associated facility for diagnosis or treatment (Merriam-Webster
Dictionary, n.d.).
Logic Model
A logic model (Figure 2) for this project was created in order to visually represent

the process and identify contributing factors to the project. Logic models are able to show
relationships between ideas and key components within the proposed work. For the
purpose of this project, key stakeholders were identified as well as proposed activities
that guide the course of the task. The model is also able to show expected outcomes as
well as later identify actual results obtained throughout the process.
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Fig. 2
Logic Model

Summary
Vaccines have been an important tool used to eliminate some of the worst disease
throughout history. As a society, we have forgotten or become indifferent to the serious
consequences of letting these diseases spread uninhibited. Continued diligence and
stricter vaccination policies are needed to keep these infections to a minimum or to
eliminate them completely; unfortunately, it may take a large-scale outbreak of one of
these easily preventable diseases to change society’s mind and current practices.
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Despite renewed information and availability of best evidence-based practice
concerning prevention measures for pertussis transmission, there remains a serious threat
to young infants and children. According to the CDC (2012), “Pertussis vaccinations
remain the single most effective strategy for prevention of infection.” Many
recommendations have been made and adopted regarding timing of booster vaccine
administration to mothers and family members, but there still is a large gap in vaccination
rates. These gaps allow for infant exposure and susceptibility to a dangerous yet
preventable disease. Infants most at risk include those under three months due to severely
limited or no immunity to pertussis.
Upon receiving a dose of the Tdap vaccination, the mother starts making
antibodies that are transferred through the placenta to the fetus, thereby conferring
passive immunity to the fetus. By vaccinating women during every pregnancy, infants are
able to start acquiring a small amount of immunity to this disease. Continued education,
guideline clarification, and research on this phenomenon will better protect future
generations from Bordetella pertussis.
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Chapter II

Literature Review

A review of literature concerning strategies for protecting infants from acquiring
pertussis infections was performed using the electronic databases of PubMed and
CINAHL. Search criteria consisted of the following:
•

Maternal Immunization

•

Tdap Vaccination

•

Pregnancy

•

Pregnancy Vaccination Rates

•

Pregnancy Vaccination Barriers

•

Infant Pertussis Transmission

•

Infant Pertussis Incidence

These topics were investigated individually as well as in combination in order to identify
relevant articles and studies. Additional articles used for the review were found among
the reference lists of the initial identified sources. All identified search results related to
maternal Tdap vaccination administration during pregnancy were not used for this
project. Sources were chosen based on studies or reports generated in the last five years
that applied to the framework of this project resultant from scholarly and peer-reviewed
14

publications. Foreign studies were included in the project if they met the above outlined
criteria for the purpose of adding generalizability to the project. The sources were then
grouped into subjects:
•

Vaccination Strategies

•

Immunogenicity

•

Vaccine Effectiveness

•

Immunization Safety

•

Barriers to Immunization Administration
Evidence

Vaccination Strategies
The concepts of cocooning, postnatal maternal administration of Tdap, and prenatal
maternal administration of the Tdap vaccine were identified as strategies against pertussis
transmission and are outlined below. Further evaluation of each will identify
effectiveness of the strategy as a stand-alone method or in combination with other
approaches. Each of these concepts play a role in protecting infants from exposure to
pertussis and/or providing immunity to infants.
Cocooning. In 2005, the (ACIP) introduced the concept of “cocooning” which is
a form of herd immunity (Terranella et al., 2013). The concept of herd immunity
postulates an individual is protected from a disease if those around them are vaccinated
against that disease. This decreases the likelihood of the individual coming into contact
with an infected person. The recommendation stipulated that family members including
fathers, grandparents, and adolescent siblings should also receive a booster vaccination,
Tdap, before or immediately after the birth of an infant if they had not been previously
15

vaccinated with the booster, allowing the ability to shield or “cocoon” the infant with
immunity.
Postnatal Administration. As a part of the cocooning strategy in 2005, mothers
received the Tdap vaccine in the immediate postpartum period, referred to as postpartum
or postnatal vaccination. This practice is still used by some providers today. According to
Castagnini et al. (2012) maternal vaccination should be included with the family goal of
immunization not just as a stand-alone measure. Their cross-sectional study discovered
that only immunizing mothers in the postpartum period made no difference in the
incidence of pertussis in infants under six months of age. The recommendation from this
study was that all family members and those frequently encountered by the infant should
receive a pertussis booster.
In an analysis performed of confirmed pertussis cases, it was determined that
infant risk was reduced by 51% when both the mother and father received the Tdap
booster; protection is further increased by 16% when older siblings and grandparents
received the Tdap booster vaccination before delivery (Quinn et al., 2014). This indicates
that increasing vaccine use in parents and other family members can help decrease infant
risk for the disease.
Prenatal Administration. In 2011, the CDC recommended that women who had
not previously received a booster Tdap immunization be immunized during the third or
late second trimester of pregnancy. The recommendation was again changed in 2012, and
women are now encouraged to receive a dose of Tdap between 27-36 weeks gestation of
every pregnancy, regardless of previous vaccination history. This dose is deemed the
prenatal or pregnancy vaccination. This allows the mother to create antibodies which will
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provide her direct immunity to pertussis. During pregnancy, these antibodies will also be
able to cross the placental barrier, to the infant, which remain present in the infant for up
to two months after birth (Abu-Raya et al., 2015). This transfer of antibodies from mother
to infant is known as indirect or passive immunity.
When compared to pre-pregnancy and postpartum Tdap administration, maternal
intrapartum vaccination has been reported to be the most effective strategy to protect
infants from contracting pertussis and is “highly protective against infant pertussis,
especially in the first two months of life” (Baxter et al., 2017). A case-control study of
pregnancy dosing from 2012-2013 in England revealed an adjusted vaccine effectiveness
of 93% after comparing incidence of pregnancy Tdap administration to postpartum
dosing in pertussis confirmed cases to those in the control group (Dabrera et al., 2015).
Practice Change Guidelines
In order to identify the most effective maternal/infant Tdap administration
strategy, a search was performed in regard to current evidence-based practice guidelines
and recommendations. A report completed by Liang et al. (2018) provides all
recommendations from the ACIP concerning the above-mentioned strategies regarding
vaccination of all persons against pertussis, diphtheria, and tetanus. The
recommendations utilized for this work were selected on the basis of appropriate age
(childbearing years), disease (pertussis), and condition (pregnancy) of the intended
population.
Pregnancy Tdap Guidelines. The ACIP recommends the following Tdap
immunization strategies for all pregnant women:
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•

Health care providers should administer a dose of Tdap during every
pregnancy, regardless of the patient’s prior Tdap vaccination history (Liang et
al., 2018).

•

Tdap may be administered at any time during pregnancy; however, for full
benefits it should be given between 27 and 36 weeks’ gestation (Liang et al.,
2018).

•

If a woman did not receive Tdap during the current pregnancy nor has she
ever received a prior dose of Tdap, then Tdap should be administered in the
immediate postpartum period (Liang et al., 2018).

•

If a woman did not receive Tdap during her current pregnancy; however, she
did receive a dose of Tdap previously, she does not require Tdap
administration in the postpartum period (Liang et al., 2018).

Recommendation Evaluation. Each vaccination recommendation set forth from
the ACIP is developed using select criteria to ensure the best and most accurate evidencebased approach. The criteria used for this is the Grading of Recommendations,
Assessment, Development, and Evaluation (GRADE) criteria. Elements assessed in this
evaluation include benefits, harms, quality of evidence, and other socioeconomic
considerations (National Center for Immunization and Respiratory Diseases, 2019). The
recommendations were further assessed using the AGREE II tool (Appendix D). The
AGREE II tool uses specific scored criteria within different domains to rate the strength
of evidence to which it is applied. It was determined the ACIP recommendations were
high in quality of evidence as well as strong recommendation strength based on amount
and level of data provided.
18

Immunogenicity
To understand the differences in protection conferred to infants by varying the
timing of the Tdap vaccination, one must consider immunogenicity. Immunogenicity is
the level of protection against an antigen. Serologic pertussis antibody levels are used to
determine the amount or level of immunogenicity or protection against this disease.
Infants receive this protection through the transplacental passage from mother to fetus of
maternal derived antibodies in response to the administration of the Tdap vaccine to the
mother during pregnancy (Gkentzi et al., 2017). Multiple studies identified in the
literature review by Gkentzi et al. (2017) measured the immunological effect of prenatal
maternal Tdap vaccination in regard to timing of the vaccination with pregnancy. In these
studies, pertussis antibody levels were compared in the mother’s blood as well as infant’s
cord blood to determine effectiveness and in some cases optimal timing of vaccine
administration.
A previous test conducted by Abu Raya et al. (2014) compared antibody serology
of mother-infant pairs. His team analyzed the maternal levels and infant cord blood levels
that were immunized at various gestational ages to determine the range for maximum
antibody referral. Women were grouped by gestational age at which they received the
Tdap vaccination. The groups were divided into those vaccinated at 27-30 weeks, 31-36
weeks, and greater than 36 weeks. Infant antibody concentrations were measured at 36
days, 72 days, and 108 days after birth. It was determined in this study that by
immunizing mothers between 27-30 weeks gestation, infants had a higher level of
antibodies present than those immunized after 31 weeks (Abu Raya et al., 2014).
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In the cohort study conducted by Winter et al. (2017), it was determined that
administration of the Tdap vaccine to mothers between the time of 27-36 weeks gestation
was more effective than those vaccinated earlier in the second trimester. Although not
held as a significant finding in this study, it was revealed that infants of mothers
vaccinated at 27-31 weeks gestation had a lower risk of pertussis than those of mothers
vaccinated between 32-36 weeks gestation (Winter et al., 2017). A prospective
observational study agreed that antibody levels of infants of mothers vaccinated earlier
within the recommended time frame had a higher level of anti-pertussis antibodies than
those born of women receiving the vaccine later (Eberhardt et al., 2016).
Healy et al. (2013) found that previously immunized women or those who
received a Tdap booster before or early in pregnancy would not have the number of
antibodies sufficient enough to pass to the infant before delivery. Maternal and infant
cord blood pairs were collected and analyzed for two years on mothers who received the
Tdap vaccine in different stages of pregnancy including preconception, early during
pregnancy, and later in pregnancy. It found no difference in antibody levels between
women vaccinated before pregnancy or early in the pregnancy, and it was determined
these levels would not be sufficient to protect the infant through two to three months of
age. This study determined the optimal time for receiving the Tdap vaccine is between
30-32 weeks (Healy et al., 2013). This protection, however, only benefits the offspring of
that particular pregnancy. Future pregnancies would require repeated immunization with
each.
According to a cohort study, Abu Raya et al. (2015) and associates confirmed that
it is necessary for women to receive the prenatal vaccination with every pregnancy due to
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waning antibody levels of the mother in the post-partum period. It was observed that
serum antibody levels were significantly reduced 9-15 months postpartum. These levels
were, however, found to be higher than their counterparts who were unimmunized during
pregnancy. The mother is able to retain immunity for herself during this time but does not
have enough available antibodies to pass to a fetus in subsequent pregnancies.
Vaccine Effectiveness
A cohort model study by Teranella et al. (2013) demonstrated the differences in
effectiveness of prenatal vaccine administration versus cocooning and infant
immunization with DTaP vaccinations after two months of age. Figures showed a
decrease in pertussis cases by 20%, hospitalizations by 19%, and deaths by 16% when
cocooning strategies were compared to infant vaccination beginning at two months of
age. Further evidence revealed an even more significant reduction in pertussis rates in
infants whose mothers received the Tdap vaccination in the antepartum period. Antibody
transfer as a result of maternal pertussis vaccination during pregnancy was shown to have
33%, 38%, and 49% decreases in pertussis cases, hospitalizations, and deaths
respectively (Teranella et al., 2013).
In response to an outbreak of pertussis in England, an observational study was
completed comparing pertussis cases in varying coverage groups. Researchers examined
the number of infant pertussis cases, hospitalizations, and deaths as a result of pertussis.
The study demonstrated an overall vaccine effectiveness of 90% with a 79% decrease in
infant mortality related to pertussis. Winters (2017), found antibodies received in utero
from maternal vaccination between 27 and 36 weeks’ gestation to be 85% more effective
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at preventing pertussis than cocooning the infant by postpartum maternal Tdap
administration.
In a retrospective cohort study conducted by Winter et al. (2017), it was
determined the antibodies received by the infant in-utero have been shown to be 85%
more effective at preventing pertussis in infants less than eight weeks old than
postpartum maternal vaccine administration. In a case control study by Dabrera et al.
(2015), an adjusted vaccine effectiveness of 93% was found by comparing incidence of
pregnancy Tdap administration to postpartum dosing.
In the United States from the years 2010 to 2015, Baxter, et al. (2017) completed
a retrospective cohort study of infants born at facilities within the health system Kaiser
Permanente Northern California (KPNC). The KPNC is a far-reaching organization
incorporating hospitals, primary care clinics, and pharmacy and laboratory services.
Participants for the cohort study were infants born greater or equal to 37 weeks gestation
into the KPNC system to mothers with established care, background, and membership
within the Kaiser Permanente healthcare system. This strategy allowed for easier
determination of immunization status as well as availability of medical records
concerning pregnancy statistics and outcomes, and incidence of infant pertussis cases. Of
the 17 infants testing positive for pertussis, only one’s mother was vaccinated during
pregnancy, resulting in a rate ratio of 0.08 with 95% confidence interval. Pregnancy Tdap
vaccination was calculated to have a 91.4% risk reduction of infant pertussis and a
calculated vaccine effectiveness of 87.9% from birth to first DTaP dose in first two
months of life (Baxter et al., 2017).
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Although there is a high-correlated vaccine effectiveness rate, the pertussis
vaccination is unable to stop every case of pertussis; however, those infants born of
mothers receiving the vaccine in the antepartum period have shown to have added health
benefits for combating the disease (Gentile et al., 2018). In order to determine effects of
maternal pertussis on disease burden and process, a surveillance study of pertussis cases
in a hospital setting before and after implementation of a national maternal intrapartum
Tdap vaccination strategy was conducted by Gentile et al. (2018). Active cases of
pertussis were identified in the population of patients at a children’s hospital between
December 1, 2003 and December 31, 2016. The establishment of the intervention was
initiated in 2012; therefore, cases in 2012 were not included in the results due to the
possibility of overlapping populations. One postintervention result identified an increase
in the average age of participants, meaning that those that did contract pertussis on
average were older at disease occurrence with a decreased incidence in the younger
population. There was also a decrease in severity of cases, resulting in less
hospitalizations. One of the most significant results was a complete reduction in mortality
from pertussis within the study period. Before the intervention, 14 cases of death from
pertussis occurred within the study period resulting in a 5.9% mortality rate. After the
intervention, there were no reported mortalities (Gentile et al., 2018).
Barriers to Immunization Administration
Despite recommendations and nationwide efforts to increase pertussis vaccination
rates among pregnant women actual vaccine coverage remains low (Gkentzi et al., 2017).
A binary logistic regression method study was conducted by Suryadevera et al. (2014)
which examined the reason for low immunity coverage. Participants were given a survey
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that inquired about factors such as knowledge about pertussis, receipt of booster
vaccination, and instruction by a health provider to obtain a booster vaccination. It was
determined there was a significant lack of knowledge concerning the disease as well as a
lack of provider recommendation to receive the vaccination (Suryadevara et al., 2014).
A study conducted by Gauld et al. (2016) identified barriers or reasons for not
getting the vaccination. Identified barriers included lack of knowledge about the pertussis
disease and the available vaccine. In some cases, women didn’t remember the topic even
coming up during prenatal visits, others identified concern about the safety of the vaccine
while pregnant. Family and anecdotal tradition was another given reason for not
receiving the vaccination. Those that did receive the Tdap vaccine recalled hearing about
it from multiple sources including their healthcare providers or settings such as health
fairs. Other participants noted receiving the vaccine due to the ease of availability from
their physician’s office or local pharmacy (Gauld et al., 2016).
A literature review conducted by Gkentzi et al. (2017) concerning vaccination
uptake strategies identified provider recommendation as being the single most effective
strategy to increase pertussis acceptance. The review also identified studies originating in
Mexico, the United Kingdom, and Australia indicating health care provider
recommendation and education regarding pertussis and the Tdap vaccination as the
strongest factors affecting maternal receipt of the vaccine. The literature review also
identified fear of vaccination safety as being the most common reason for refusing the
vaccine (Gkentzi et al., 2017).
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Vaccination Safety
To test the safety of administering vaccines to pregnant women a phase I,
randomized, double-masked, placebo-controlled clinical trial was conducted by Munoz et
al. (2014). The study found no adverse outcomes for mothers or infants who received the
prenatal Tdap vaccine. It was noted that all had healthy newborns at and following
delivery. The most common adverse effect noted with this study was injection site pain
for the mother.
Researchers in New Zealand completed a prospective observational study
regarding the safety of women receiving the Tdap vaccination during pregnancy. The
study consisted of 739 participants that were followed for four weeks after receiving the
Tdap vaccination at various times during the intrapartum period. While 31 different
serious adverse events (SAEs) occurred during this time, none of the SAEs were able to
be linked or attributed to the mother receiving the pertussis vaccination. They concluded
that the maternal Tdap vaccination was generally well tolerated by mothers and led to no
adverse fetal or pregnancy outcomes (Petousis-Harris et al., 2016).
Lastly, the above-mentioned review of literature by Gkentki et al. (2017)
consisted of a systematic review of 47 studies evaluating maternal Tdap vaccination
safety, effectiveness, immunogenicity, and coverage. In regard to safety, a combined
138,277 pregnancies were identified as receiving the Tdap vaccination among the 47
studies. The identified studies individually looked at SAEs such as preterm birth,
stillbirth, low birth weight, duration of hospitalization, obstetric complications, and
overall neonatal or maternal outcomes. None of the studies identified a difference in
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maternal or neonatal outcome related to the mother receiving the Tdap vaccination when
compared to unvaccinated counterparts (Gkentzi et al., 2017).
Summary
Despite renewed information and availability of best evidence-based practice
concerning prevention measures for pertussis transmission, pertussis remains a serious
threat to young infants and children. Many recommendations have been made and
adopted regarding timing of booster vaccine administration to mothers, family members
and other contacts; still, there is a large gap in vaccination rates. These gaps allow for
infants to be exposed and susceptible to a dangerous yet preventable disease. Many do
not realize there is a large gap in protection; others rely on the vaccination of others
within the community in order to not take steps at vaccination for themselves and their
family.
Antibody referral from the mother to the fetus has shown the most significant
effectiveness limiting the transmission of pertussis to infants. Demonstrated vaccine
effectiveness of maternal intrapartum vaccination ranges from 85-93% in limiting
pertussis related illness. Of those contracting the illness, maternal receipt of the vaccine
in the prenatal period has been effectively shown to reduce the severity of the disease
process. Combining strategies such as prenatal administration of the Tdap vaccination
with cocooning has been shown to further increase an infant’s protection. These
techniques should be used together to allow for maximum effectiveness against this
disease. Vaccination safety had been proven time and again. The next step is to address
the most common reason for nonacceptance--lack of provider recommendation. Going
forward it is important to further educate the public as well as healthcare professionals on
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the importance of these strategies in order to allow them to make their own best-informed
decisions. Healthcare professionals must be knowledgeable of the best practice guidelines
and communicate this knowledge with their patients. In light of the information revealed
with this literature review, assessing the healthcare professionals’ knowledge and practice
recommendation regarding maternal intrapartum Tdap vaccination administration was the
focus of this project in order to decrease the pertussis disease burden in our most
vulnerable population.
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Chapter III

Methodology

Immunizing pregnant mothers with Tdap has been shown to be the most effective
way in preventing acquisition of and/or limiting the severity of pertussis in young infants.
Despite numerous recommendations and efforts to increase Tdap administration to this
population, a large number of mothers remain unimmunized during pregnancy (Gkentzi
et al., 2017). Research has also shown that lack of provider recommendation and
education regarding Tdap as a main contributing factor of those not receiving the vaccine
(Suryadevara et al., 2014).
Project Design
This chapter details the design of the completed research project. The intended
purpose of this project was to (1) evaluated Tdap administration knowledge and practice
of obstetric health care providers as well as clinical and supportive staff, i.e. nurses,
medical aides, and others: (2) provided an educational in-service regarding the
importance of Tdap administration and current recommendations to providers and
supportive staff, and (3) evaluated knowledge gained and/or intent to change current
practice by physicians and supportive staff as a result of the educational in-service.
The study obtained data in the form of a pretest regarding the pre-intervention
knowledge of the participants regarding pertussis, strategies to limit pertussis
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transmission to infants, as well as whether they discuss pertussis with their patients.
Further data was obtained by the posttest comparing the participants’ perceived increase
in knowledge regarding pertussis and evaluated the participants’ plan to incorporate that
knowledge in their future practice.
Setting
The Ascension Medical Group St. John Clinic employs multiple physicians and
offers the only obstetrics coverage in the city of Bartlesville, Oklahoma. The clinic has
two divisions in obstetrics care: the first is a group of three obstetrician/gynecologists and
the other is a group of four family practice physicians providing obstetrics care and
services. Each of the practices employ a number of other healthcare professionals
including nurse practitioners, nurses, and other support staff. Each office cares for a
diverse range of patients, both racially/ethnically and socioeconomically.
Target Population
The target participants for the study consisted of providers and supportive staff
working in the St. John Clinics’ family practice and obstetrician/gynecological offices in
Bartlesville, Oklahoma. Providers include family practice and obstetric/gynecologic
physicians. Supportive staff included nurses (registered nurses and licensed practical
nurses) and aides (certified medical aide, certified nurse aide). Projected estimate of the
number of participants for data collection was 30 to 40 staff members in various
positions.
Recruitment and Inclusion/Exclusion Criteria
Those participating in the study included healthcare professionals and support
staff attending an educational in-service offered once on a specific day for each office
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group. The group gathers multiple times per month during the lunch hour to discuss
current medical topics and treatments. Permission was obtained from the physicians and
office managers to present information regarding pertussis and current Tdap
administration guidelines for pregnant patients. Other participants were welcome to join
the educational in-service; however, data collected from them was excluded from the data
pool if their position did not apply to those educating patients on Tdap and pertussis or
giving the Tdap vaccination.
Protection of Human Subjects
An application for approval of investigations involving the use of human subjects
was completed and submitted to the Pittsburg State University Institution Review Board
(IRB) for approval to complete the study. According to the Pittsburg State University
human subjects’ guidelines, this study qualifies for exempt status. Subjects included in
the study were of age to consent for themselves (over eighteen years of age) and did not
include any vulnerable or protected individuals or groups such as minors, prisoners, or
pregnant patients themselves. The study was presented to the human subjects committee
in order to be reviewed and approved.
Participation in the study was on a voluntary basis. Verbal disclosure was given
before beginning the presentation that a participant’s answers would not be revealed to
their employer or other coworkers in order to prevent retribution. In order to maintain
confidentiality, pre-tests were previously numbered. Participants were instructed to
number their post-test with the same number that was on their pre-test. Providing
corresponding numbers on the tests ensured accuracy and continuity of results while
maintaining privacy of the individuals. Individual results were maintained as confidential
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and were not and will not be revealed to persons outside of the conductor of the study and
those completing computations of the data if applicable.
Ethical Considerations
Ethical considerations for the study included anonymity of participants and their
answers obtained from the questionnaires. Demographics on the questionnaires were
evaluated to determine education levels of the participants in regard to position and years
of practice. Care was taken to ensure these demographics were not able to identify a
participant.
Instruments
An instrument specific for this study was unable to be found. For this reason, a
questionnaire instrument was developed in order to assess current knowledge and
practice for each of the participants regarding patient pertussis and Tdap education and
administration. Demographics included on the questionnaire assess the position or role of
the participant, the type of practice in which they worked, and length of time in that
position. The pre and posttests contain Likert-type, dichotomous, and multiple
choice/multiple mark questions. The questions evaluated the current knowledge and
practice of the participant and practice of the office setting in which they work. Three
questions were select all that apply to assess office practice, barriers to patient Tdap
education, and barriers to Tdap administration.
Procedure
After receiving approval from the IRB for the project, physicians and office
managers from each of the prospective offices were contacted to gain consent for the
educational in-service. Data for the study was obtained from pre-test and post-test
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questionnaires with an educational in-service completed between the tests. The
participants were given a packet containing both a numbered pretest, a posttest (which the
participant numbered to match the pre-test), a pregnancy Tdap informational handout
(appendix C), and a paper copy of the PowerPoint presentation. Participants completed
the pretest before the educational portion of the presentation. The posttests were removed
from the packet and completed after the presentation. Both surveys were returned to the
original packet then collected by the presenter and placed in a locked case. The
participants were able to keep the other printed information and any notes they had taken.
Questions on the pretest aimed to determine participants’ knowledge and practice
regarding pertussis and Tdap vaccination information and guidelines. The first question
identified the participant’s job status as provider, supportive staff, or other. An additional
question on the pretest regarding perceived patient barriers or reasons for refusal to
accept Tdap administration was included to gauge possible future interventions.
The presentation consisted of a PowerPoint presentation on a screen and
participants were given a paper form of the presentation in order for participants to
review information at a later time. Information presented consisted of pertussis definition
and severity, strategies aimed at combating pertussis, as well as current guidelines and
recommendations regarding proper maternal Tdap administration and timeline regarding
pregnancy. A question and answer period followed. Once the question and discussion
time was completed, the participants were instructed to complete the posttest before
leaving. The posttest consisted of a number of the same questions from the pretest
reworded in order to gauge information learned and the participants intention of practice
change in the future.
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Additional information was given in the form of a paper handout from the CDC.
The handout, titled “You Can Start Protecting Your Infant from Whooping Cough Before
Birth,” is an information sheet produced by the CDC. This article details the risks and
harms associated with pertussis, steps pregnant women can take in order to protect their
infant from whooping cough, and also the safety of the Tdap vaccine. It is endorsed by
the American Academy of Pediatrics, the American Academy of Family Physicians,
American College of Obstetricians and Gynecologists, and the American College of
Nurse-Midwives (CDC, 2019b). This sheet was provided in order to demonstrate the
information that should be given to and discussed with all mothers regarding pertussis
and the Tdap vaccine. Evaluation of this information sheet was done using the Patient
Medical Educational Tool (PMET). This tool evaluates patient education material for
ease of understanding by patients and those without high health literacy. It rates 26
individual aspects of the education material on clarity, simplification of verbiage, layout,
and design. These aspects are scored as disagree, agree, or not applicable. The agree
responses receive a point, disagree responses receive no point, and not applicable
responses are not counted in the total possible. The points are calculated then divided by
the number of points possible which gives a percentage on the strength of the material.
The CDC’s handout received a score of 93.7% on understandability, and a score of 83%
for actionability. Points reduced for scoring this material was due to lack of visual aids on
the handout. Despite the limited visual aids, the material is easy to read and understand
and has clear instructions to the reader on how to combat pertussis.
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Outcomes
Evaluation Measures. Evaluation of the data collected determined the provider’s
and support staff’s current knowledge of the pertussis disease as well as current practice
prior to receiving the educational presentation. These values were then compared to those
obtained after the in-service to determine if knowledge levels increased. It also evaluated
the intention of the participant to improve future practice in regard to discussing Tdap
vaccination with patients and their families. These measures are discussed further in the
next chapter.
Instrument Linked to Measures. The measurement tool used for this study was
a pretest and posttest format. These tools were developed specifically for this project. In
order to test the validity and significance of the tools, they were distributed to health care
professionals in the field of obstetrics to determine ease of understandability and
significance of application to the project. To score the tools, a rubric was used on each of
the questions except the demographics. Items were scored on a 1-4 scale regarding the
significance to the study. A score of 1 indicates the question is not relevant to the study, 2
indicates the study is somewhat relevant, 3 indicates quite relevant, while 4 indicates very
relevant. The average score for validity of the tool was 37/40. Additional comments and
input from evaluators were considered and implemented on some items to improve
understandability and ease of use of the tools.
Methods of Analysis. Excel spreadsheets were utilized in order to complete
statistical analysis of the data. Statistics gathered evaluated the knowledge of pertussis
and Tdap in all participants combined. Further evaluation will examine the differences in
practice among types of healthcare professionals including comparing family practice and
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OB/GYN physicians as well as supportive staff to evaluate the population most in need of
the intervention and possible continued efforts in the future. Likewise, comparing and
contrasting of individual responses was completed on additional topics, such as current
practice discussing these topics with patients. Data collected from the survey following
the educational presentation evaluated the individuals’ change in knowledge regarding
pertussis and Tdap as well as their intention to implement it in their future practice.
Visual aids used for demonstration of acquired data included bar graphs and pie charts.
Plan for Sustainability
Sustainability is described by the Institute for Healthcare Improvement as
“locking in the progress made by an improvement initiative” (Moran et al., 2017).
Sustainability of the study will rely on continued evaluation of knowledge and
implementation of educational training regarding current Tdap vaccination strategies in
the future. As strategies and recommendations regarding Tdap administration during
pregnancy have changed throughout the years, it will be the responsibility of the
providers and supportive staff to stay current with recommendations that affect their
patient population. The Tdap handout provided in this presentation can serve as a guide
to help healthcare professionals and patients with information regarding Tdap. Current
guidelines regarding Tdap administration should be intermittently evaluated by a
specified person within each clinic setting in order to assess for recommendation
changes.
The pregnancy Tdap handout distributed during the presentation is available as a
free download and is available on the CDC website (CDC, 2019b). Expected incurred
cost of sustaining this project would be low. Costs would be the result of ink and paper in
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order to produce the information sheet to distribute to patients. These costs are expected
to be low relative to the current use of a printing service for the healthcare system.
Summary
Lack of maternal Tdap vaccination represents a great potential for severe health
disparities in infants. In order to address these gaps in coverage, all healthcare
professionals must be able to educate patients on the importance of Tdap vaccination and
proper timing of the vaccine during every pregnancy. Adherence to the ACIP Tdap
administration guidelines has been shown to decrease the incidence as well as severity of
pertussis in young infants (Gentile et al., 2018). The goal of this project was to increase
provider awareness of pertussis vaccination administration practices and evaluate the
adherence to those guidelines. Educating all healthcare professionals including nurses
and other staff further increases the ability to confer knowledge to pregnant patients and
their families the dangers of pertussis and the importance of receiving the vaccine.
Furthermore, infants will receive passive immunity by way of antibodies from their
mother while in utero and mothers will receive a boosted immunity from pertussis.
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Chapter IV

Results Evaluation

The data collected with the surveys were descriptive in nature. The intended
purpose of this project and data collection was to (1) evaluate current Tdap
administration knowledge and practice of obstetric health care providers as well as
clinical and supportive staff, i.e. nurses, medical aides, and others: (2) provide
educational in-service regarding the importance of Tdap administration and current
recommendations to providers and supportive staff, and (3) evaluate knowledge gained
and/or intent to change current practice by physicians and supportive staff as a result of
the educational in-service. The long-term goals of this study are to improve maternal
intrapartum Tdap vaccination acceptance rates, thereby leading to increased rates of
immunity against pertussis in newborns up to two months of age.
Results
An educational in-service was provided to each of the two types of Ascension
Medical Group St. John clinics offering obstetrics care in Bartlesville, Oklahoma.
Immediately prior to the presentation, participants were provided with and completed a
pre-numbered pre-test. Pre-test results that were compiled included information such as
participant demographics (position, type of clinic, and time at current position), as well as
current individual perceived knowledge regarding pertussis and Tdap. Further
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information obtained in the survey related to participants’ personal and healthcare facility
practice regarding Tdap education and vaccine administration. Participants were then
shown a PowerPoint regarding pertussis as well as current CDC recommendations
regarding maternal intrapartum Tdap vaccination strategies. Immediately following the
presentation, a short question and answer period was completed. Participants were then
given a post-test and instructed to write the number on the pretest number on this survey.
The post-test included participants’ perceived increase in knowledge regarding pertussis
and Tdap recommendations. Other information obtained included their intention to
discuss this information more with their patients and to improve Tdap administration
rates.
Demographics
Pre and posttest surveys were distributed among those present for the in-service in
each office setting. The presentation was offered one time to each of the OB/GYN and
family practice settings at Ascension Medical Group St. John Clinic in Bartlesville,
Oklahoma. Information obtained about the participants consisted of; type of office
setting, position, and years at position. Demographic data was included only on the
pretests. This information was used to contrast and compare knowledge regarding Tdap
vaccine administration knowledge and practice among participants’ positions, office type,
and number of years of experience.
Practice Setting. A total number of 23 respondents (N=23) participated in the
surveys and in-services. Participants were asked to differentiate if they worked in the
obstetrician/gynecologist office setting or the family practice office. The ratio of
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respondents from each type of office consisted of 52% (n=12) from the family practice
office and 48% (n=11) from the obstetrics/gynecology office (Figure 3).
Participant Role. Participants were next asked to identify their position or role
(Figure 4). Possible choices included providers (physician, nurse practitioner, or
physician’s assistant), nurses (registered nurse or licensed practical nurse), assistive staff
(certified medical assistant or medical technician), and other office staff (Figure 3).
Responses included five (22%) providers, eleven (48%) nurses, four (17%) assistive staff
members, and three (13%) office staff members.
Figure 3
Demographics
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Participant’s Years of Experience. The largest group of participants, 35%
(n=8), have been in their current position or role for 6-10 years (Figure 3). The second
largest group, 20% (n=6), reported greater than 20 years of experience. The remainder of
respondents reported experience among 0-2 years for 17% (n=4), 3-5 year 13% (n=3),
and 11-20 years 9% (n=2).
Roles per Practice Type. Roles were further evaluated according to office or
practice type (Figure 4). Of the respondent providers, two were obstetrician/gynecologists
while three were physicians providing family practice care with obstetrical services. The
largest group represented in the data consisted of seven nurses from the family practice
office setting. Four nurses were representative of the OB/GYN group.
Figure 4
Roles per Practice Type
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Background
The background section of the survey was only included on the pretest surveys.
Information gathered in this section included the current practice aspects of the different
clinics. Participants were asked if the clinic in which they worked provided patients with
informational handouts regarding the Tdap vaccination. They were also asked if their
offices administered the Tdap vaccination within the clinic, as well as the reason if they
did not administer the vaccine within the clinic. Finally, it asked about patient provided
reasons for not receiving the vaccination.
Office Tdap Practices. Of the two types of offices surveyed, OB/GYN and
family practice, all respondents from both offices reported that each of the clinics offered
and administered maternal Tdap vaccinations to their intrapartum patients. One provider
indicated in the survey, as well as in the discussion following the presentation that they
did not administer the vaccination in the office setting to Medicaid patients due to lack of
reimbursement for the vaccine by Medicaid. In this particular office, patients with
Medicaid coverage were instructed to go to the health department to receive the
vaccination.
It was reported that both office types did give informational handouts to patients
regarding pertussis and Tdap vaccination. Upon further discussion, the informational
handouts provided by both offices were for pertussis and Tdap in general and not specific
for pertussis and Tdap during pregnancy. Discussion regarding the specific nature of the
maternal intrapartum Tdap vaccine was discussed among participants. It was considered
important by participants to obtain more information for patients regarding the role of the
Tdap vaccination during pregnancy.

41

Questionnaire
The questionnaire portion of the survey included in both the pretest and post-test.
Question topics remained the same; however, the manner of asking the question was
changed. Questions presented on the pretest sought to identify individuals’ current
practice and their perceived knowledge regarding pertussis prevention and Tdap
vaccination strategies. Posttest questions were worded to determine participants’
perceived increase in knowledge regarding the topics as well as their intention to change
their practice in the future.
Familiarity with Current Pregnancy Tdap Recommendations. All participants
indicated that they were familiar with recommendations for vaccinating against pertussis
during pregnancy (Figure 5). Of these, 70% (n=16) reported they were strongly aware of
recommendations while 30% (n=7) reported they were aware. Following the in-service
participants were asked to answer the statement “I am more familiar with
recommendations for vaccinating against pertussis during pregnancy.” Again, all
participants indicated that they were more familiar with Tdap recommendations during
the post-test, with 95% of participants (n=22) reporting that they “strongly agreed with
the statement of being more familiar with recommendations.
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Figure 5
Familiarity with Pregnancy Tdap Recommendations

Confident of Pertussis/Tdap Knowledge. Participants were next asked about
their confidence regarding their knowledge of pertussis and the Tdap vaccine when
discussing those vaccines with their patients/families (Figure 6). Of the participants
(N=23), 61% (n=14), “strongly agreed” prior to the in-service that they felt confident in
their knowledge of the pertussis disease as well as maternal Tdap recommendations. Of
the remaining participants, 26% (n=6) “agreed” while 13% (n=30) “disagreed” that they
felt confident regarding their knowledge in order to pertussis and Tdap with their patients
prior to the educational presentation. Following the presentation, all participants either
“agreed” or “strongly agreed” that they had an increase in knowledge regarding Tdap
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vaccination following the presentation. Furthermore, 91% (n=21) of participants reported
that they “strongly agreed” that they felt an increase in confidence in their knowledge
regarding Tdap vaccination strategies following the presentation.
Figure 6
Confidence in Tdap Knowledge

Tdap Discussed with Patients. The next question sought to determine the
individual practices of participants (Figure 7). They were asked in the pretest if they
currently discussed pertussis and the Tdap vaccine with patients. Of those surveyed,
(n=6) reported they did not discuss Tdap with patients at that time. In the posttest, all
participants responded that they intend to discuss pertussis and the Tdap vaccine with
their patients in the future.
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Figure 7
Tdap Discussed with Patients

Barriers to Discussing Tdap with Patients. As a follow-up to the previous
question, participants were asked to identify their perceived barriers to discussing
pertussis and the Tdap vaccine with their patients (Figure 8). This was a multiple-choice
question as participants may several barriers affecting their ability to talk with patients. A
majority of participants (60%) reported no barrier to discussing pertussis and Tdap
vaccinations with patients. Others did report, however, that time constraint and lack of
knowledge prevented them from talking with patients. Following the educational
presentation, an increased number of participants, 78% (n=18), reported that they will
have no perceived barrier in discussing these subjects with patients in the future. Some
participants still identified lack of time and lack of knowledge pertussis as barriers to
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discussing pertussis and Tdap strategies with patients. Time constraints are an
increasingly large factor in healthcare. Improved use of time, time management
strategies, delegation of tasks, and strong informational handouts could be important
strategies to address this problem. In regard to continued lack of individuals’ knowledge,
further individualized research into this subject could be beneficial.
Figure 8
Barriers to Discussing Tdap with Patients

Tdap Vaccine to Family Members. As a part of the herd immunity strategy of
cocooning, family members including fathers, adolescent siblings, grandparents, and
other close contacts are encouraged to receive the Tdap vaccination before the birth of the
infant. This allows the family member to build immunity before the infant is born in
order to keep from passing pertussis to the infant in the first few months (Castagnini et al.
2012). After receiving this information during the in-service, a larger percentage of
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respondents strongly agreed to being aware of the need for family members to receive the
Tdap vaccination (Figure 9).
Figure 9
Aware of the Need for Family Members to Receive Tdap Vaccine

When asked about current practice of recommending to patients that family
members receive the Tdap vaccination, all participants reported that they do this (Figure
10). After discussion of the importance family members receiving the vaccine, 95%
(n=22) of respondents reported they “strongly agree” while the remaining respondent
“agrees” to plan to encourage family members to receive the vaccine in the future.
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Figure 10
Recommend Tdap Vaccine to Family Members

Additional Statistical Analyses
In addition to the questions posed for the purpose of this study, an extra question
was included on the pre-test about the most frequently given reasons that patients failed
to receive the maternal Tdap vaccination. Participants were able to select from a number
of reasons patients have given for declining the Tdap vaccination (Figure 11). According
to the surveyed healthcare professionals, financial concern (10 responses) was the most
common reason for patients to decline the vaccination. Safety concerns and lack of
patient knowledge regarding pertussis and the vaccine tied (9 responses each) as the next
most common reasons for patients to decline the vaccination. Five respondents reported
pain from the vaccine as the primary reason given by patients who decline the
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vaccination. Lastly, one respondent reported religion was another stated barrier for
patients.
Figure 11
Patient Reason for Declining Tdap Vaccine

Summary
This chapter discussed the results of the project to identify healthcare
professionals’ current knowledge level, attitude, and belief regarding national maternal
Tdap vaccination guidelines. It also described how these beliefs changed as a result of
provided education regarding pertussis and vaccination strategies. The study revealed that
a majority of those participating in the in-service believed they already knew about
current maternal intrapartum Tdap vaccination strategies. However, following an
educational in-service, the respondents reported that they learned new information from
the presentation.
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Chapter V

Discussion

The purpose of this study was to evaluate the current knowledge level, attitude,
and belief of physicians, advanced practice providers, and support staff of obstetric
providing clinics at Ascension Medical Group St. John Clinic in Bartlesville, Oklahoma,
regarding national maternal Tdap vaccination guidelines. The second aspect of the study
sought to determine if and/or how the knowledge, attitude, and beliefs of these healthcare
professionals would change after receiving education regarding Tdap administration
guidelines. The study provided an educational presentation to inform participants on the
current maternal intrapartum Tdap vaccination strategies to improve healthcare
professionals’ knowledge regarding the vaccination strategy. The overall goal of this
study was to improve healthcare professionals’ awareness of the current guidelines
regarding maternal intrapartum Tdap vaccination.
Relationship of Outcomes to Research
Identified barriers in the literature to maternal intrapartum Tdap vaccination
included patient lack of knowledge about the pertussis disease and the available vaccine.
In some cases, women did not remember the topic being mentioned during prenatal visits.
Those receiving the Tdap vaccine recalled hearing about it from multiple sources
including their healthcare providers (Gauld et al., 2016). It has been shown that when
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information is offered by a reliable and trusted source such as a healthcare professional, a
patient is more inclined to follow guidelines.
As results of this study indicate, some healthcare professionals were not confident
in their knowledge regarding pertussis prevention and maternal intrapartum Tdap
vaccination strategies for this population. They also reported they were not likely to
discuss this topic with patients. After completion of the in-service, all participants
surveyed either “agreed” to “strongly agreed” that they would discuss these subjects with
their patients.
Statistically, patients have reported receiving the vaccine due to the ease of
availability from their physician’s office or local pharmacy (Gauld et al., 2016). Patients
who are offered vaccination in the clinic setting are more likely to be vaccinated than
those being instructed to go elsewhere (New et al., 2016). One provider in the survey and
discussion following the presentation noted they did not administer the vaccination in the
office setting to Medicaid patients due to lack of reimbursement for the vaccine by
Medicaid. In this particular office, patients with Medicaid coverage were instructed to go
to the health department to receive the vaccination. Directing a patient to another location
to receive the vaccination decreases the likelihood of the patient receiving the vaccine.
Upon further review of reimbursement regarding the intrapartum Tdap vaccine, other
offices within the same St. John groups reported full reimbursement of the vaccine and
administration costs from Medicaid when the vaccine is coded under pregnancy. It was
determined that reimbursement did exist for patients under Medicaid for the Tdap
vaccination. Since this determination, the provider has started vaccinating every willing
patient in their office regardless of insurance status.
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Evaluation of Theoretical Framework
The Health Belief Model (Figure 1.1) was the theoretical framework used for
illustration purposes of this project. The major assumptions of the Health Belief Model
postulate that a person will take a desired action if they believe the benefits and calls to
action outweigh the risks and barriers of such action. In the case of maternal intrapartum
Tdap vaccine administration, information and advice given by healthcare professionals
has been identified as a large influencing factor on whether or not someone accepts the
vaccination. By increasing healthcare professionals’ knowledge regarding pertussis and
interventions to prevent pertussis one can strengthen the likelihood that they will be able
to pass this knowledge to their patients increasing the call to action.
According to the results of this study, a majority of healthcare professionals
surveyed expressed confidence regarding their knowledge about pertussis as well as the
recommendations regarding maternal intrapartum Tdap administration; however, all
participants reported that the educational in-service increased their knowledge regarding
the subject. Likewise, all participants in the study reported the likelihood that they will
discuss this topic with their patients in the future. This suggests that all who participated
in the in-service learned some new information that will enable them to educate their
patients on the importance of pertussis prevention during pregnancy.
Evaluation of Logic Model
The logic model (Figure 1.2) created for this study incorporated the intended
audience or study participants (physicians/providers, nurses, support staff) as well as the
intervention (pretest, in-service, posttest). Expected immediate effects or results of the
activity included increased awareness and knowledge of current maternal intrapartum
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Tdap vaccination guidelines. According to results of the surveys, all participants
indicated an increase in knowledge. The next expected effect was practice changes
regarding recommendations. All participants expressed an intention to discuss pertussis
and maternal Tdap vaccine administration with patients.
Other expected results of the project listed in the logic model have yet to be
determined. These outcomes include increased rates of maternal intrapartum Tdap
vaccination which, as evidenced by literature, will lead to a decrease in incidence,
severity, and/or infant death rates in relation to pertussis cases. Further study will be
required to determine the effect of this study on these outcomes. One proposed evaluation
of expected results would be to complete a chart review of rates of Tdap administration
retroactive to the offering of the educational in-service and compare those rates to those
occurring after the intervention.
Limitations
One observed limitation of the study included participant survey size. During the
time of the in-services, it was noted that one OB/GYN physician as well as one of the
family practice group’s physicians were out on medical leave. Two nurse practitioners
were also out of the office on the day of the presentation. These absences further
decreased the size of the study as those nurses and/or supportive staff were not available
to attend the in-service.
This project focused on the obstetrics providers’ offices within a single health
system, Ascension Medical Group St. John, in one community, Bartlesville, Oklahoma. If
participants had been included from a number of health systems and a greater number of
communities, it is anticipated the results would have been more diverse and varied in
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response to healthcare professionals’ knowledge, recommendation, as well as practice
regarding maternal Tdap administration.
Finally, limitations introduced by way of the instrument include the ability to
accurately determine provider knowledge regarding Tdap recommendations. Participants
were instructed to consider their own knowledge regarding current Tdap
recommendations before the in-service was given. This perceived knowledge of the
individual may have been greater than what it actually was. Since the study revealed that
91% of the participants responded with a “strongly agree” response to a question
evaluating that participants knowledge increased regarding Tdap administration, it could
be possible that some participants did not know as much as they initially thought.
Implications for Future Research
Effects of the educational in-service on overall Tdap vaccine administration rates
and thus decreases in rates and/or severity of pertussis cases was unable to be determined
due to the expedited nature of the study. An extended time period that would allow for
evaluation of vaccine rates retroactively in comparison to those after the intervention
would provide a better example of the results of the in-service. This would be completed
by a comprehensive chart review of patients in the inpatient labor and delivery setting
regarding the acceptance of the maternal Tdap vaccination. A retroactive review of
administration rates would have been compared to the vaccination rates after the inservice was conducted. This comparison would be able to demonstrate an actual
improvement of vaccination rates as a result of healthcare professional education if one
occurred.
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Based on the limited number of participants provided by the selected setting for
this study, a larger scale intervention could be the basis for another study. This study
would be proposed to incorporate multiple settings and/or communities that may identify
even larger gaps in knowledge regarding pertussis prevention as well as Tdap vaccination
strategies. Likewise, informing other healthcare professionals, such as inpatient
obstetrical nurses may serve to improve the overall knowledge of all healthcare
professionals providing care to this population.
Participants in this study were asked to identify the reasons patients frequently
give for declining the maternal intrapartum Tdap vaccination. Future research or
consideration should go into evaluating these barriers in the current system. Patient
education from providers should be tailored to address these concerns. It would also be
helpful to poll patients directly on their concerns regarding the vaccination or barriers to
receiving the vaccination. These results may prove to be similar or different than those
previously identified. Regardless of the result, these factors should be addressed with
patients and information should be identified and shared. The results to this question were
provided to the office managers and providers in order to further identify needs that may
be addressed in the future.
The complete project will be given to and/or discussed with the department
manager of the hospital’s inpatient obstetrics unit at Jane Phillips Medical Center in
Bartlesville, Oklahoma. The same educational in-service that was provided for the
outpatient clinics will be provided for the inpatient nurses. At that time, current pertussis
recommendations will be presented and discussed with this group. Current practices and
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procedures regarding maternal Tdap vaccination strategies in the inpatient setting will be
reviewed to determine if they are in line with national recommendations.
Implications for Practice
Healthcare professionals are one of the biggest contributing factors for
influencing health behaviors in their patient populations. It is important for healthcare
professionals to be knowledgeable of diseases and other health disparities. It is also
imperative for them to stay up to date with current guidelines regarding strategies to
eliminate or limit these health disparities in order to improve the health of their patients.
It was reported that both office types provide patients with informational handouts
to patients regarding pertussis and Tdap vaccination. Upon further discussion, the
informational handouts were for pertussis and Tdap in general and not specifically about
pertussis and Tdap during pregnancy. Discussion regarding the specific nature of the
maternal intrapartum Tdap vaccine was discussed among study participants. It was
considered important by participants to obtain more information for patients regarding
the role of the Tdap vaccination during pregnancy.
The handout provided by the CDC (Appendix C) was discussed as a good piece of
information to provide obstetric patients. As discussed in the handout provided to
participants, mothers have the unique ability to start protecting their babies from pertussis
before a child is even born. There is a short time period in which this protection can be
maximized in order to offer infants the best protection available to them. Discussion of
this important topic with mothers needs to be well timed and effective in order to rely the
importance of the situation to mothers. Once an infant is born, it is too late to confer this
immunity to them.

56

Conclusion
Pertussis continues to be a prevalent threat to children. This threat has been shown
to be even greater among infants under two months due to them not yet being immunized.
In the past, herd immunity was used as the sole strategy to offer protection from pertussis
to infants. More recently, it was discovered that administering a Tdap vaccination to
mothers during the intrapartum period offers this vulnerable population the greatest
chance of protection against pertussis. This protection offers infants, at best, the ability to
avoid contracting pertussis or, at least, decreases the severity and/or death rates for those
infants who do contract the illness. Historically, lack of instruction by healthcare
providers was one of the major reasons cited by patients for not receiving the Tdap
vaccine (Gauld et al, 2016). By keeping healthcare professionals up to date regarding
pertussis prevention as well as current Tdap vaccination recommendations, they will be
better prepared and informed about the subject in order to improve and facilitate
discussion with patients.
Participants of this study were provided with verbal as well as paper copies of
information regarding pertussis and Tdap vaccination strategies. It is the intention of this
survey was to improve healthcare professionals’ knowledge of this disease and
prevention in order to address this subject more fully with their patients. Improved dialog
with patients has been shown to increase vaccination rates, leading to a decrease in
pertussis cases and/or the severity of the illness. It is important that all healthcare
professionals share in this knowledge and responsibility as patient safety relies upon it.
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APPENDIX

Appendix A:
Tdap Administration Survey

Number____
Pre-Test

Demographics:
1. What is your position or role?
___Provider (doctor, nurse practitioner, physician’s assistant)
___Nurse (RN, LPN)
___Assistive Personnel (CMA, Tech, Aide)
___Other (office staff, etc.)
2. # of years in position/role
___0-2 years
___3-5 years
___6-10 years
___11-20 years
___>20 years
3. Type of Practice you work in:
___Family Practice
___OB/GYN
___Other: _______
Background:
4. Does your office give patients informational handouts regarding the Tdap vaccine?
___Yes
___No
___Unsure
5. Are Tdap (tetanus/diphtheria/pertussis) vaccinations administered in your office?
___Yes (skip to #7)
___No (if no, answer #6)
___Unsure
6. Please list reason the Tdap vaccine is not given in the office. (Select all that apply)
___Cost
___Time constraint
___Unsure
___Other: ________________________________________
7. What reasons do patients give for declining the Tdap vaccine? (Select all that apply)
___Lack of recommendation by physician
___Lack of knowledge of necessity
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___Financial burden
___Unsure of where to get it
___Fear of pain from shot
___Safety concerns (side effects)
___Religion
___Other: specify______________________
___N/A
Questionnaire:
1. I am familiar with recommendations for vaccinating against pertussis during
pregnancy?
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
2. I feel confident in my knowledge of pertussis and the tetanus/diphtheria/pertussis
(Tdap) vaccine to talk with my patients/families?
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
3. I currently discuss pertussis (whooping cough) and the Tdap vaccine with patients?
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
___N/A
4. What barriers do you have to informing patients about the need for Tdap? (select all)
___None, I talk with all my patients and their families
___Lack of time
___Lack of knowledge about current pertussis vaccination strategies and guidelines
___Perceived lack of interest from patients and families
___Lack of knowledge of waning (decreasing) immunity to pertussis
___Other (please list): _____________________________________
5. I am aware of the need for family members of obstetric patients to get Tdap booster
vaccinations due to declining immunity?
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
6. I encourage my obstetric patients’ family members to receive the Tdap vaccine?
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___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
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Appendix B:
Tdap Administration Survey

Number____
Post-Test

Questionnaire:
1. I am more familiar with recommendations for vaccinating against pertussis during
pregnancy.
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
2. I have increased confidence in my knowledge of pertussis and the
tetanus/diphtheria/pertussis (Tdap) vaccine to talk with my patients/families?
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
3. I plan to discuss pertussis (whooping cough) and the Tdap vaccine with patients in the
future?
___ Strongly Agree
___Agree
___Disagree
___Strongly Disagree
4. Barriers that continue to exist in regard to informing patients about the need for Tdap
in the future include: (select all that apply)
___None, I will talk with all my patients and their families
___Lack of time
___Lack of knowledge about current vaccination strategies and guidelines
___Perceived lack of interest from patients and families
___Lack of knowledge of waning (decreasing) immunity to pertussis
___Other (please list):______________________________________
5. I am more aware of the need for family members of obstetric patients to get Tdap
booster vaccinations due to declining immunity?
___Strongly Agree
___Agree
___Disagree
___Strongly Disagree
6. I plan to make recommendations to my obstetric patients’ family members to receive
the Tdap vaccine?
___Strongly Agree

68

___Agree
___Neutral
___Disagree
___Strongly Disagree
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Appendix C:
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Appendix C (cont.): (posterior)
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Appendix D: AGREE II
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